NASDAQ$RCKT
Rocket Pharmaceuticals Inc · Q2 2022 earnings
Q2 2022 earnings · · Investor relations
Briefing
Rocket Pharmaceuticals reported financial results for the second quarter of 2022 and provided updates on key pipeline developments and operational milestones.
Rocket Pharmaceuticals reported positive results across all four clinical programs and made progress toward manufacturing readiness. The company maintains a healthy operational cash runway into the first half of 2024.
- Reported positive safety data from pediatric cohort of Phase 1 Danon Disease study; efficacy update on track for late Q3 2022.
- Announced top-line data from pivotal Phase 2 trial for severe LAD-I with 100% overall survival at one year; regulatory filings anticipated in first half of 2023.
- Primary endpoint met for Fanconi Anemia pivotal Phase 2 trial, FDA dialogue initiated for BLA planning; continued data readouts expected in Q4 2022.
- Achieved cGMP readiness milestone for AAV manufacturing facility in Cranbury, N.J.
Headline financials
Revenue & EPS history
Rocket · Revenue · Quarterly
$0
Forward guidance
Rocket Pharmaceuticals expects resources will be sufficient to fund its operating expenses and capital expenditure requirements into the first half of 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2022
+0.8%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-1.9%
Avg return
30 days after
51%
23 / 45 earnings
Positive
+18.2%
Q1 2023
Best reaction
-17.7%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.4% | -6.0% | -29.0% | |
| Q4 2025 | +10.8% | +6.4% | -16.8% | |
| Q3 2025 | +0.3% | +2.2% | +2.8% | |
| Q1 2025 | -0.6% | +0.9% | -55.7% | |
| Q4 2024 | +0.5% | -2.0% | -19.3% | |
| Q3 2024 | -0.7% | -8.8% | -21.0% | |
| Q2 2024 | -3.6% | -8.8% | -14.5% | |
| Q1 2024 | -0.5% | -3.2% | -1.6% | |
| Q4 2023 | +5.0% | +4.3% | -6.9% | |
| Q3 2023 | -2.4% | -11.6% | +23.1% | |
| Q2 2023 | -2.6% | -4.2% | -7.8% | |
| Q1 2023 | +18.2% | +16.4% | +23.0% | |
| Q4 2022 | +5.9% | +14.8% | -7.7% | |
| Q3 2022 | -6.0% | -10.8% | +9.9% | |
| Q2 2022 | +4.3% | +12.3% | +1.5% | |
| Q1 2022 | -15.2% | -17.2% | +20.4% | |
| Q4 2021 | +4.3% | -2.6% | -11.4% | |
| Q3 2021 | +10.3% | +8.0% | -30.2% | |
| Q2 2021 | -4.9% | -13.9% | -1.8% | |
| Q1 2021 | -3.9% | -6.5% | +3.6% | |
| Q4 2020 | -0.7% | -1.8% | -16.9% | |
| Q3 2020 | +5.3% | +0.2% | +9.2% | |
| Q2 2020 | +6.3% | +10.6% | -8.1% | |
| Q1 2020 | -1.5% | +12.7% | +8.5% | |
| Q4 2019 | -1.1% | -7.7% | -30.3% | |
| Q3 2019 | +10.2% | +4.0% | +50.6% | |
| Q2 2019 | +4.5% | -3.2% | +0.4% | |
| Q1 2019 | +1.6% | -8.7% | -14.6% | |
| Q4 2018 | -4.7% | -2.1% | +27.4% | |
| Q3 2018 | -1.0% | -12.5% | -17.6% | |
| Q2 2018 | +3.8% | -5.3% | +9.0% | |
| Q1 2018 | +6.5% | +19.8% | +23.2% | |
| Q4 2017 | -0.4% | +0.2% | -19.2% | |
| Q3 2017 | +2.0% | +15.7% | +3.6% | |
| Q2 2017 | +8.3% | +16.7% | +13.3% | |
| Q1 2017 | -9.6% | +0.0% | -1.4% | |
| Q4 2016 | +8.7% | -4.3% | +24.6% | |
| Q3 2016 | +4.5% | +4.5% | +1.5% | |
| Q2 2016 | +0.1% | +2.7% | +1.8% | |
| Q1 2016 | -17.7% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -6.9% | — | — | |
| Q2 2015 | -4.1% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro